Key result
Administration of MAT.Ang-1 after the onset of sepsis significantly reduced LPS-induced macromolecular leak (31.6 vs 80.7, p<0.001) and improved microvascular blood flow.
Why the study?
Does the angiopoietin-1 variant MAT.Ang-1 reduce microvascular dysfunction in a murine model of sepsis?
Population
Male C3H/HeN mice with endotoxemia induced by intraperitoneal injection of lipopolysaccharide.
Comparison
MAT.Ang-1 33 μg administered intravenously 20… vs LPS alone, saline control, and MAT.Ang-1 alone.
Design
Preclinical
Follow-up
24 hours
Authors
Loading...
May protect microcirculation in murine sepsis; leaves open clinical translation to human septic shock.
Does the angiopoietin-1 variant MAT.Ang-1 reduce microvascular dysfunction in a murine model of sepsis?
Absolute Event Rate: 31.6% vs 80.7%
p-value: p=<0.001
Administration of the stable angiopoietin-1 variant MAT.Ang-1 after the onset of sepsis protects the microcirculation from endotoxemia-induced vascular dysfunction by reducing inflammation.
Alfieri et al. (2012) studied Sepsis (LPS-induced endotoxemia) (n=24). MAT.Ang-1 vs. LPS alone was evaluated on Macromolecular leak (normalised grey level) at 24 hours (p=<0.001). Administration of MAT.Ang-1 after the onset of sepsis significantly reduced LPS-induced macromolecular leak (31.6 vs 80.7, p<0.001) and improved microvascular blood flow.